Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 2
1998 2
1999 5
2000 14
2001 15
2002 22
2003 38
2004 36
2005 39
2006 34
2007 36
2008 29
2009 41
2010 39
2011 57
2012 41
2013 43
2014 58
2015 45
2016 53
2017 40
2018 46
2019 73
2020 66
Text availability
Article attribute
Article type
Publication date

Search Results

817 results
Results by year
Filters applied: . Clear all
Page 1
Probiotics and prebiotics in ulcerative colitis.
Derikx LA, Dieleman LA, Hoentjen F. Derikx LA, et al. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):55-71. doi: 10.1016/j.bpg.2016.02.005. Epub 2016 Feb 9. Best Pract Res Clin Gastroenterol. 2016. PMID: 27048897 Review.
The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora with probiotics and prebiotics is an attractive strategy in the management of ulcerative colitis. ...However, given the pr …
The intestinal microbiota is one of the key players in the etiology of ulcerative colitis. Manipulation of this microflora wit …
A Probiotic for Ulcerative Colitis: The Culture Wars Continue.
Abraham BP, Quigley EMM. Abraham BP, et al. Dig Dis Sci. 2018 Jul;63(7):1678-1680. doi: 10.1007/s10620-018-5097-1. Dig Dis Sci. 2018. PMID: 29785650 No abstract available.
A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.
Bjarnason I, Sission G, Hayee B. Bjarnason I, et al. Inflammopharmacology. 2019 Jun;27(3):465-473. doi: 10.1007/s10787-019-00595-4. Epub 2019 May 3. Inflammopharmacology. 2019. PMID: 31054010 Free PMC article. Clinical Trial.
BACKGROUND: There is considerable interest in the possible importance of the gut microflora in the pathophysiology of the inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD). Probiotics offer a potential adjuvant treatmen …
BACKGROUND: There is considerable interest in the possible importance of the gut microflora in the pathophysiology of the inflammatory bowel …
Probiotics for Gastrointestinal Conditions: A Summary of the Evidence.
Wilkins T, Sequoia J. Wilkins T, et al. Am Fam Physician. 2017 Aug 1;96(3):170-178. Am Fam Physician. 2017. PMID: 28762696 Free article. Review.
The most-studied species include Lactobacillus, Bifidobacterium, and Saccharomyces. However, a lack of clear guidelines on when to use probiotics and the most effective probiotic for different gastrointestinal conditions may be confusing for family physicians and th …
The most-studied species include Lactobacillus, Bifidobacterium, and Saccharomyces. However, a lack of clear guidelines on when to use pr
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Tursi A, et al. Am J Gastroenterol. 2010 Oct;105(10):2218-27. doi: 10.1038/ajg.2010.218. Epub 2010 Jun 1. Am J Gastroenterol. 2010. PMID: 20517305 Free PMC article. Clinical Trial.
OBJECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis
OBJECTIVES: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end …
Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.
Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, Tan B, Wang XY. Shen ZH, et al. World J Gastroenterol. 2018 Jan 7;24(1):5-14. doi: 10.3748/wjg.v24.i1.5. World J Gastroenterol. 2018. PMID: 29358877 Free PMC article. Review.
Ulcerative colitis (UC) is an inflammatory disease that mainly affects the colon and rectum. ...FMT can also restore immune dysbiosis by inhibiting Th1 differentiation, activity of T cells, leukocyte adhesion, and production of inflammatory factors. Probiotics
Ulcerative colitis (UC) is an inflammatory disease that mainly affects the colon and rectum. ...FMT can also restore immune dy
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. Singh S, et al. Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18. Gastroenterology. 2019. PMID: 30576642 Free PMC article. Review.
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists. ...Focused questions included the following: (1) comparative effectiveness and tolerabil …
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed …
Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
Parian A, Limketkai BN. Parian A, et al. Curr Pharm Des. 2016;22(2):180-8. doi: 10.2174/1381612822666151112145033. Curr Pharm Des. 2016. PMID: 26561079 Review.
Inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease are chronic relapsing and remitting chronic diseases for which there is no cure. ...Specifically, the efficacy and adverse effects of vitamin D, fish oil, probiotics, pre …
Inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease are chronic relapsing and remitting c …
Probiotics in Inflammatory Bowel Disease.
Abraham BP, Quigley EMM. Abraham BP, et al. Gastroenterol Clin North Am. 2017 Dec;46(4):769-782. doi: 10.1016/j.gtc.2017.08.003. Epub 2017 Oct 3. Gastroenterol Clin North Am. 2017. PMID: 29173520 Review.
Strategies that target the microbiota have emerged as potential therapies and, of these, probiotics have gained the greatest attention. Data derived from animal models of IBD have revealed the potential of several bacterial strains to modify the natural history of IBD. How …
Strategies that target the microbiota have emerged as potential therapies and, of these, probiotics have gained the greatest attentio …
The gut microbiota and host health: a new clinical frontier.
Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. Marchesi JR, et al. Gut. 2016 Feb;65(2):330-9. doi: 10.1136/gutjnl-2015-309990. Epub 2015 Sep 2. Gut. 2016. PMID: 26338727 Free PMC article. Review.
The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation....
The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidenc …
817 results
Jump to page
Feedback